Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition

▤ Summary

Galmed Pharmaceuticals completed its acquisition of Colospan and made Colospan a wholly owned subsidiary. The transaction gives Galmed a commercial-stage medical device with CE marking in the EU and approval in Israel, plus a dedicated reimbursement code in Germany. Galmed says the deal supports a faster European rollout of CG-100 and reduces immediate dilution for shareholders through revised cash and earnout terms. The company also plans to use real-world patient data to support Colospan’s U.S. pivotal study. The acquisition expands Galmed’s GI platform across both drug and device commercialization.

▦ Linked Companies